Academy of Military Medical Sciences

The Academy of Military Medical Sciences (AMMS) of the PLA Academy of Military Science () is a Chinese military medical research institute. It was established in Shanghai in 1951. It has been based in Beijing since 1958.
In October 2011 the drug "Night Eagle", developed to help soldiers cope with sleep deprivation during missions, was unveiled in an exhibition marking the institute's 60th anniversary.
In December 2014, the Chinese government announced that the Academy of Military Medical Sciences had developed an Ebola virus vaccine candidate that had been approved for clinical trials.
COVID-19 vaccine.
During the COVID-19 pandemic, the AMMS partnered with CanSino Biologics to develop a COVID-19 vaccine (later known as Convidecia). The development team, led by Chen Wei, registered an experimental COVID-19 vaccine for Phase 1 trial on 17 March 2020 to test its safety. The vaccine was tried on 108 healthy volunteers in Wuhan. In April 2020, the vaccine entered Phase 2 to test its effectiveness on 500 volunteers. The vaccine was the first one approved outside of clinical trials in an expedite decision, which authorized its use only by the Chinese military.